Why the study?
Does KRH-594 improve diabetic nephropathy and hyperlipidemia in diabetic spontaneously hypertensive rats compared to candesartan?
Population
Streptozotocin (STZ)-induced diabetic unilateral nephrectomized spontaneously hypertensive rats (DM-1K-SHR)
Comparison
KRH-594 administered orally for 16 weeks vs Candesartan cilexetil administered orally for 16…
Design
Preclinical
Follow-up
16 weeks
Authors
Loading...
Hypothesis-generating for dual nephropathy-lipid effects in diabetic hypertension models; leaves open translation to patients.
Does KRH-594 improve diabetic nephropathy and hyperlipidemia in diabetic spontaneously hypertensive rats compared to candesartan?
KRH-594, a novel AT1 receptor antagonist, ameliorates diabetic nephropathy and uniquely improves hyperlipidemia in a hypertensive diabetic rat model.
Inada et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: